The company has not provided details on how local operations will be affected.
1 minute to read
The Danish pharmaceutical company Novo Nordisk, the maker of GLP-1 for diabetes and obesity, announced it is reducing its workforce globally by 9,000 people by the end of 2026.
A company spokesperson declined to provide specific figures for the Boston operations, stating that “this is a global transformation,” and Novo Nordisk sites will each be impacted differently. The company has not yet finalized its plans for Boston…